On April 4, 2023,
Cantor Fitzgerald
maintained
coverage of Biohaven Pharmaceutical Holding with
a Overweight recommendation.
Analyst Price Forecast Suggests 77.58% Upside
As of March 30, 2023,
the average one-year price target for Biohaven Pharmaceutical Holding is $24.68.
The forecasts range from a low of $21.21 to a high of $28.35.
The average price target represents an increase of 77.58% from its latest reported closing price of $13.90.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Biohaven Pharmaceutical Holding
is $0MM.
The projected annual non-GAAP EPS
is -$4.44.
What are Large Shareholders Doing?
Stifel Financial
holds 5,620K shares
representing 8.24% ownership of the company.
In it’s prior filing, the firm reported owning 3,072K shares, representing
an increase
of 45.34%.
The firm
decreased
its portfolio allocation in BHVN by 100.00% over the last quarter.
Janus Henderson Group
holds 4,563K shares
representing 6.69% ownership of the company.
In it’s prior filing, the firm reported owning 550K shares, representing
an increase
of 87.95%.
The firm
decreased
its portfolio allocation in BHVN by 74.55% over the last quarter.
Suvretta Capital Management
holds 3,849K shares
representing 5.64% ownership of the company.
In it’s prior filing, the firm reported owning 62K shares, representing
an increase
of 98.40%.
The firm
increased
its portfolio allocation in BHVN by 13,826.88% over the last quarter.
XBI – SPDR Biotech ETF
holds 3,479K shares
representing 5.10% ownership of the company.
In it’s prior filing, the firm reported owning 504K shares, representing
an increase
of 85.51%.
The firm
decreased
its portfolio allocation in BHVN by 46.06% over the last quarter.
RP Management
holds 2,937K shares
representing 4.30% ownership of the company.
In it’s prior filing, the firm reported owning 1,111K shares, representing
an increase
of 62.16%.
The firm
decreased
its portfolio allocation in BHVN by 38.15% over the last quarter.
What is the Fund Sentiment?
There are 472 funds or institutions reporting positions in Biohaven Pharmaceutical Holding.
This is a decrease
of
128
owner(s) or 21.33% in the last quarter.
Average portfolio weight of all funds dedicated to BHVN is 0.36%,
a decrease
of 62.86%.
Total shares owned by institutions increased
in the last three months by 6.42% to 73,706K shares.
The put/call ratio of BHVN is 3.14, indicating a
bearish
outlook.
Biohaven Background Information
(This description is provided by the company.)
Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer’s disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
